Company: Regeneron
Tags: pipeline, general
Say what you want about the home office politics, Dupixent access is genuinely easier to get than anything else in the derm/allergy space right now. I just converted three accounts that were Rinvoq-first for AD and it was surprisingly smooth — payers are opening up. The prior auth burden has dropped noticeably in the last two quarters. Field team is solid in my territory, no real conflict with the IBD launch overlap. If you're considering a move, the portfolio story right now is actually compelling. Just go in with realistic comp expectations, the base isn't as high as some competitors.
22 upvotes · 0 comments